Skip to main content
Top
Published in: Health and Quality of Life Outcomes 1/2005

Open Access 01-12-2005 | Review

Patient-Reported Outcome and Quality of Life Instruments Database (PROQOLID): Frequently asked questions

Published in: Health and Quality of Life Outcomes | Issue 1/2005

Login to get access

Abstract

The exponential development of Patient-Reported Outcomes (PRO) measures in clinical research has led to the creation of the Patient-Reported Outcome and Quality of Life Instruments Database (PROQOLID) to facilitate the selection process of PRO measures in clinical research. The project was initiated by Mapi Research Trust in Lyon, France. Initially called QOLID (Quality of Life Instruments Database), the project's purpose was to provide all those involved in health care evaluation with a comprehensive and unique source of information on PRO and HRQOL measures available through the Internet.
PROQOLID currently describes more than 470 PRO instruments in a structured format. It is available in two levels, non-subscribers and subscribers, at http://​www.​proqolid.​org. The first level is free of charge and contains 14 categories of basic useful information on the instruments (e.g. author, objective, original language, list of existing translations, etc.). The second level provides significantly more information about the instruments. It includes review copies of over 350 original instruments, 120 user manuals and 350 translations. Most are available in PDF format. This level is only accessible to annual subscribers. PROQOLID is updated in close collaboration with the instruments' authors on a regular basis. Fifty or more new instruments are added to the database annually.
Today, all of the major pharmaceutical companies, prestigious institutions (such as the FDA, the NIH's National Cancer Institute, the U.S. Veterans Administration), dozens of universities, public institutions and researchers subscribe to PROQOLID on a yearly basis. More than 800 users per day routinely visit the database.
Appendix
Available only for authorised users
Literature
1.
go back to reference Wilke RJ, Burke LB, Erickson P: Measuring treatment impact: a review of patient-reported outcomes and other efficacy endpoints in approved product labels. Control Clin Trials 2004, 25: 535–552. 10.1016/j.cct.2004.09.003CrossRef Wilke RJ, Burke LB, Erickson P: Measuring treatment impact: a review of patient-reported outcomes and other efficacy endpoints in approved product labels. Control Clin Trials 2004, 25: 535–552. 10.1016/j.cct.2004.09.003CrossRef
2.
go back to reference Acquadro C, Berzon R, Dubois D, Leidy NK, Marquis P, Revicki D, Rothman M, PRO Harmonization Group: Incorporating the patient's perspective into drug development and communication: an ad hoc task force report of the Patient-reported Outcomes (PRO) Harmonization Group meeting at the Food and Drug Administration, February 16, 2001. Value Health 2003, 6: 522–531. 10.1046/j.1524-4733.2003.65309.xPubMedCrossRef Acquadro C, Berzon R, Dubois D, Leidy NK, Marquis P, Revicki D, Rothman M, PRO Harmonization Group: Incorporating the patient's perspective into drug development and communication: an ad hoc task force report of the Patient-reported Outcomes (PRO) Harmonization Group meeting at the Food and Drug Administration, February 16, 2001. Value Health 2003, 6: 522–531. 10.1046/j.1524-4733.2003.65309.xPubMedCrossRef
3.
go back to reference The ERIQA Group: Assessing Treatment Impact Using Patient-Reported Outcomes (PROs): Challenges in Study Design, Conduct and Analysis. Meeting Report (Paris, May 10–11, 2004). Patient-Reported Outcomes Newsletter 2005,3(Special):1–16. The ERIQA Group: Assessing Treatment Impact Using Patient-Reported Outcomes (PROs): Challenges in Study Design, Conduct and Analysis. Meeting Report (Paris, May 10–11, 2004). Patient-Reported Outcomes Newsletter 2005,3(Special):1–16.
4.
go back to reference Muller-Buhl U, Engeser P, Klimm HD, Wiesemann A: Quality of life and objective disease criteria in patients with intermittent claudication in general practice. Fam Pract 2003, 20: 36–40. 10.1093/fampra/20.1.36PubMedCrossRef Muller-Buhl U, Engeser P, Klimm HD, Wiesemann A: Quality of life and objective disease criteria in patients with intermittent claudication in general practice. Fam Pract 2003, 20: 36–40. 10.1093/fampra/20.1.36PubMedCrossRef
5.
go back to reference Bolling-Sternevald E, Lauritsen K, Talley NJ, Junghard O, Glise H: Is it possible to predict treatment response to a proton pump inhibitor in functional dyspepsia? Aliment Pharmacol Ther 2003, 18: 117–124. 10.1046/j.1365-2036.2003.01651.xPubMedCrossRef Bolling-Sternevald E, Lauritsen K, Talley NJ, Junghard O, Glise H: Is it possible to predict treatment response to a proton pump inhibitor in functional dyspepsia? Aliment Pharmacol Ther 2003, 18: 117–124. 10.1046/j.1365-2036.2003.01651.xPubMedCrossRef
6.
go back to reference Eton DT, Fairclough DL, Cella D, Yount SE, Bonomi P, Johnson DH, Eastern Cooperative Oncology Group: Early change in patient-reported health during lung cancer chemotherapy predicts clinical outcomes beyond those predicted by baseline report: results from Eastern Cooperative Oncology Group Study 5592. J Clin Oncol 2003, 21: 1536–1543. 10.1200/JCO.2003.07.128PubMedCrossRef Eton DT, Fairclough DL, Cella D, Yount SE, Bonomi P, Johnson DH, Eastern Cooperative Oncology Group: Early change in patient-reported health during lung cancer chemotherapy predicts clinical outcomes beyond those predicted by baseline report: results from Eastern Cooperative Oncology Group Study 5592. J Clin Oncol 2003, 21: 1536–1543. 10.1200/JCO.2003.07.128PubMedCrossRef
7.
go back to reference Chassany O, Sagnier P, Marquis P, Fulleton S, Aaronson N: Patient Reported Outcomes and Regulatory Issues: the Example of Health-related Quality of Life – A European Guidance Document for the Improved Integration of HRQL Assessment in the Drug Regulatory Process. Drug Inf J 2002, 36: 209–238.CrossRef Chassany O, Sagnier P, Marquis P, Fulleton S, Aaronson N: Patient Reported Outcomes and Regulatory Issues: the Example of Health-related Quality of Life – A European Guidance Document for the Improved Integration of HRQL Assessment in the Drug Regulatory Process. Drug Inf J 2002, 36: 209–238.CrossRef
8.
go back to reference Leidy NK, Revicki DA, Geneste B: Recommendations for evaluating the validity of quality of life claims for labeling and promotion. Value Health 1999, 2: 113–127. 10.1046/j.1524-4733.1999.02210.xPubMedCrossRef Leidy NK, Revicki DA, Geneste B: Recommendations for evaluating the validity of quality of life claims for labeling and promotion. Value Health 1999, 2: 113–127. 10.1046/j.1524-4733.1999.02210.xPubMedCrossRef
Metadata
Title
Patient-Reported Outcome and Quality of Life Instruments Database (PROQOLID): Frequently asked questions
Publication date
01-12-2005
Published in
Health and Quality of Life Outcomes / Issue 1/2005
Electronic ISSN: 1477-7525
DOI
https://doi.org/10.1186/1477-7525-3-12

Other articles of this Issue 1/2005

Health and Quality of Life Outcomes 1/2005 Go to the issue